Joachim M Baehring MD

Associate Professor of Medicine (Medical Oncology), of Neurology and of Neurosurgery; Clinical Program Leader, Brain Tumor Program, Smilow Cancer Hospital

Specialties & Subspecialties

Cancer Center, Yale: Brain Tumor Center | Hematology Program

Neurology: Stroke Center, Yale-New Haven | Brain Tumors and Neuro-Oncology


Education & Training

  • M.D., Johannes-Gutenberg-University of Mainz (1994)
  • Fellow, University Hospital Heidelberg / Germany , Molecular Oncology (1994 - 1996)
  • Intern, Medical College of Pennsylvania/Philadelphia, PA , Internal Medicine (1996 - 1997)
  • Resident, Hahnemann University Hospital Philadelphia, PA , Neurology (1997 - 2000)
  • Fellow, Massachusetts General Hospital, Boston, MA , Neuro-Oncology (2000 - 2002)

Patient Care

Accepts New Patients? Yes | Patient Type: Adult | Accepts referrals from patients

Clinical Interests

Chemotherapy of primary brain tumors (high-grade gliomas, central nervous system lymphoma); neurological complications of brain cancer; general neurology; molecular markers of cancer.

Cancers Treated


Board Certifications

  • Neurology, Board Certified (2001)

Clinical Trials

ConditionsStudy Title
Brain and Nervous SystemA Phase I/II Study of the Combination of BKM120 and Bevacizumab in Patients with Refractory Solid Tumors (Phase I) and Relapsed/Refractory Glioblastoma Multiforme (Phase II)
Brain and Nervous SystemA Randomized Phase 3 Open Label Study of Nivolumab versus Bevacizumab and Multiple Phase 1 Safety Cohorts of Nivolumab or Nivolumab in Combination with Ipilimumab Across Different Lines of Glioblastoma
Brain and Nervous SystemTAU-2014-1: Phase I Trial of Mibefradil Dihydrochloride with Hypofractionated Re-Irradiation Therapy in Treating Patients with Recurrent Glioblastoma Multiforme (GBM)
Bladder, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Female Genital, Other Male Genital, Pancreas, Prostate, Rectum, Soft Tissue, Stomach, and ThyroidA Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies

Edit Profile